PMID: 2103150Jan 1, 1990Paper

1,000 renal transplants at the Massachusetts General Hospital: improved allograft survival for high-risk patients without regard to HLA matching

Clinical Transplants
F L DelmonicoA Benedict Cosimi

Abstract

Excellent allograft survival is now routinely accomplished following renal transplantation. Changes in immunosuppression have resulted in a significant improvement in early survival for recipients of primary LRD and CD allografts. In our series, crossmatching techniques which accurately assess alloantibody reactivity and not the degree of HLA mismatch have also permitted successful transplantation of such high-risk groups as recipients of second transplants and highly sensitized recipients. However, a yearly attrition rate of allograft loss persists for all recipients. These long-term observations stress the need for newer approaches to immunosuppression in the future, which include protocols that allow for an indefinite tolerance to incompatible donor antigens.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
M D StegallJ M Gloor
Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera
F Dahm, M Weber
© 2021 Meta ULC. All rights reserved